“Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 6, Nov. 2024, p. s442, https://doi.org/10.25251/skin.8.supp.442.